Unfortunately this recent setback has effectively given our competitors almost 12 more months to gain market share, and before everyone screams side effects not all patients will suffer from side effects from the competitions products and once finding something that works will stick with it. Those potential customers will be lost to SB. Also dermatologists will get success with other products and continue to prescribe them.
I had dreamt of early retirement but now I can hope that my kids will get rich off off this one because the development of of our other products now seems a very long way off. Thems the breaks I guess.
Just my opinion.
New Hartley Analyst report on Bot, page-26
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $527.6M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 50000 | 3 |
View Market Depth
| Last trade - 14.01pm 20/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable